Regulation of transient site-specific copy gain by MicroRNA

Journal of Biological Chemistry

Volumn 291, Issue 10, 2016, Pages 4862-4871

  Black, Joshua C ^a   Zhang, Hailei ^c   Kim, Jaegil ^c   Getz, Gad ^b,c   Whetstine, Johnathan R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; DRUG THERAPY; PLATINUM COMPOUNDS; TUMORS;

BREAST CANCER CELLS; BREAST TUMOR; COPY NUMBER; DEMETHYLASE; DRUG RESISTANCE GENES; MOLECULAR MECHANISM; SITE-SPECIFIC; UP-REGULATION;

RNA;

CISPLATIN; HISTONE DEMETHYLASE; HISTONE DEMETHYLASE KDM4; MICRORNA; MICRORNA 137; MICRORNA 23A 3P; MICRORNA 23B 3P; UNCLASSIFIED DRUG; CKS1B PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE; KDM4A PROTEIN, HUMAN; MIRN137 MICRORNA, HUMAN; MIRN23 MICRORNA, HUMAN;

ARTICLE; CKS1B GENE; CONTROLLED STUDY; COPY NUMBER VARIATION; ENZYME INHIBITION; ENZYME REGULATION; GENE EXPRESSION; GENETIC RESISTANCE; HUMAN; HUMAN CELL; ONCOGENE; PRIORITY JOURNAL; TRANSIENT SITE SPECIFIC COPY GAIN; UPREGULATION; BREAST TUMOR; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; TUMOR CELL LINE;

BREAST NEOPLASMS; CDC2-CDC28 KINASES; CELL LINE, TUMOR; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; MICRORNAS;

EID: 84962192092     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M115.711648     Document Type: Article

References (43)

1. Hanahan, D., and Weinberg, R. A. (2011) Hallmarks of cancer: the next generation. Cell 144, 646-674
2. Dimova, I., Orsetti, B., Theillet, C, Dimitrov, R., and Toncheva, D. (2009) Copy number changes in 1q21.3 and 1q23.3 have different clinical relevance in ovarian tumors. Balkan J. Med. Genet. 12, 29-37
3. Diskin, S. J., Hou, C, and Glessner., J. T., Attiyeh, E. F., Laudenslager, M., Bosse, K., Cole, K., Mossé, Y. P., Wood, A., Lynch, J. E., Pecor, K., Diamond, M., Winter, C, Wang, K., Kim, C, et al. (2009) Copy number variation at 1q21.1 associated with neuroblastoma. Nature 459, 987-991
4. Fonseca, R., Van Wier, S. A., Chng, W. J., Ketterling, R., Lacy, M. Q., Dispenzieri, A., Bergsagel, P. L., Rajkumar, S. V., Greipp, P. R., Litzow, M. R., Price-Troska, T., Henderson, K. J., Ahmann, G. J., and Gertz, M. A. (2006) Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia 20, 2034-2040
5. Inoue, J., Otsuki, T., Hirasawa, A., Imoto, I., Matsuo, Y., Shimizu, S., Taniwaki, M., and Inazawa, J. (2004) Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma. Am. J. Pathol. 165, 71-81
6. Giulino-Roth, L., Wang, K., and MacDonald., T. Y., Mathew, S., Tam, Y., Cronin, M. T., Palmer, G., Lucena-Silva, N., Pedrosa, F., Pedrosa, M., Teruya-Feldstein, J., Bhagat, G., Alobeid, B., Leoncini, L., Bellan, C, et al. (2012) Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes. Blood 120, 5181-5184
7. Goeze, A., Schlüns, K., Wolf, G., Thäsler, Z., Petersen, S., and Petersen, I. (2002) Chromosomal imbalances of primary and metastatic lung adenocarcinomas. J. Pathol. 196, 8-16
8. Lestini, B. J., Goldsmith, K. C, Fluchel, M. N., Liu, X., and Chen., N. L., Goyal, B., Pawel, B. R., and Hogarty, M. D. (2009) Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists. Cancer Biol. Ther. 8, 1587-1595
9. Vrana, J. A., and Bieszczad., C. K., Cleaveland, E. S., Ma, Y., Park, J. P., and Mohandas., T. K., and Craig, R. W. (2002) An MCL1-overexpressing Burkitt lymphoma subline exhibits enhanced survival on exposure to serum deprivation, topoisomerase inhibitors, or staurosporine but remains sensitive to 1-β-D-arabinofuranosylcytosine. Cancer Res. 62, 892-900
10. Weir, B. A., and Woo., M. S., Getz, G., Perner, S., Ding, L., Beroukhim, R., Lin, W. M., and Province., M. A., Kraja, A., Johnson, L. A., Shah, K., Sato, M., Thomas, R. K., and Barletta., J. A., Borecki, I. B., et al. (2007) Characterizing the cancer genome in lung adenocarcinoma. Nature 450, 893-898
11. Black, J. C, Atabakhsh, E., Kim, J., Biette, K. M., Van Rechem, C, Ladd, B., Burrowes, P. D., Donado, C, Mattoo, H, Kleinstiver, B. P., Song, B., Andriani, G., Joung, J. K., Iliopoulos, O., Montagna, C, et al. (2015) Hypoxia drives transient site-specific copy gain and drug-resistant gene expression. GenesDev. 29, 1018-1031
12. Black, J. C, Manning, A. L., Van Rechem, C, Kim, J., Ladd, B., Cho, J., Pineda, C. M., Murphy, N., Daniels, D. L., Montagna, C, Lewis, P. W., Glass, K., Allis, C. D., Dyson, N.J., Getz, G., and Whetstine, J. R. (2013) KDM4A lysine demethylase induces site-specific copy gain and rereplication of regions amplified in tumors. Cell 154, 541-555
13. Black, J. C, and Whetstine, J. R. (2015) Too little O2 Too much gain. Cell Cycle 14, 2869-2870
14. Mishra, S., and Whetstine, J. R. (2016) Different facets of copy number changes: permanent, transient, and adaptive. Mol. Cell. Biol. 10.1128/MCB.00652-15
15. Black, J. C., Allen, A., Van Rechem, C., Forbes, E., Longworth, M., Tschöp, K., Rinehart, C., Quiton, J., Walsh, R., Smallwood, A., and Dyson., N. J., and Whetstine, J. R. (2010) Conserved antagonism between JMJD2A/KDM4A and HP1gamma during cell cycle progression. Mol. Cell 40, 736-748
16. Tan, M. K., and Lim., H. J., and Harper, J. W. (2011) SCF(FBXO22) regulates histone H3 lysine 9 and 36 methylation levelsbytargeting histone demethylase KDM4A for ubiquitin-mediated proteasomal degradation. Mol. Cell. Biol. 31, 3687-3699
17. Van Rechem, C., Black, J. C., Abbas, T., Allen, A., Rinehart, C. A., and Yuan., G. C., Dutta, A., and Whetstine, J. R. (2011) The SKP1-Cul1-F-box and leucine-rich repeat protein 4 (SCF-FbxL4) ubiquitin ligase regulates lysine demethylase 4A (KDM4A)/Jumonji domain-containing 2A (JMJD2A) protein. J. Biol. Chem. 286, 30462-30470
18. Van Rechem, C., Black, J. C., Greninger, P., Zhao, Y., Donado, C., Burrowes, P. D., Ladd, B., and Christiani., D. C., Benes, C. H., and Whetstine, J. R. (2015) A coding single nucleotide polymorphism in lysine demethylase KDM4A associates with increased sensitivity to mTOR inhibitors. Cancer Discov. 5, 245-254
19. Ha, M., and Kim, V. N. (2014) Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 15, 509-524
20. Khattar, V., and Thottassery, J. V. (2013) Cks1: structure, emerging roles and implications in multiple cancers. J. Cancer Ther. 4, 1341-1354
21. Martín-Ezquerra, G., Salgado, R., Toll, A., Baró, T., Mojal, S., Yébenes, M., Garcia-Muret, M. P., Solé, F., Quitllet, F. A., Espinet, B., and Pujol, R. M. (2011) CDC28 protein kinase regulatory subunit 1B (CKS1B) expression and genetic status analysis in oral squamous cell carcinoma. Histol. Histopathol. 26, 71-77
22. Shaughnessy, J. (2005) Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology 10, 117-126
23. Shi, L., Wang, S., Zangari, M., Xu, H., and Cao., T. M., Xu, C., Wu, Y., Xiao, F., Liu, Y., Yang, Y., Salama, M., Li, G., Tricot, G., and Zhan, F. (2010) Overexpression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance. Oncotarget 1, 22-33
24. Beroukhim, R., Getz, G., Nghiemphu, L., Barretina, J., Hsueh, T., Linhart, D., Vivanco, I., and Lee., J. C., Huang, J. H., Alexander, S., Du, J., Kau, T., Thomas, R. K., Shah, K., Soto, H., et al. (2007) Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc. Natl. Acad. Sci. U.S.A. 104, 20007-20012
25. Beroukhim, R., and Mermel., C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., McHenry, K. T., Pinchback, R. M., Ligon, A. H., Cho, Y. J., Haery, L., et al. (2010) The landscape of somatic copy-number alteration across human cancers. Nature 463, 899-905
26. Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068
27. Garcia, D. M., Baek, D., Shin, C., Bell, G. W., Grimson, A., and Bartel, D. P. (2011) Weak seed-pairing stability and high target-site abundance decrease the proficiency of lsy-6 and other microRNAs. Nat. Struct. Mol. Biol. 18, 1139-1146
28. Lewis, B. P., and Burge., C. B., and Bartel, D. P. (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120, 15-20
29. Fujita, Y., Yagishita, S., Hagiwara, K., Yoshioka, Y., Kosaka, N, Takeshita, F., Fujiwara, T., Tsuta, K., Nokihara, H., Tamura, T., Asamura, H., Kawaishi, M., Kuwano, K., and Ochiya, T. (2015) The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer. Mol. Ther. 23, 717-727
30. Wang, X. C, Tian, J., and Tian., L. L., Wu, H. L., Meng, A. M., and Ma., T. H., Xiao, J., Xiao, X. L., and Li, C. H. (2009) Role of Cks1 amplification and overexpression in breast cancer. Biochem. Biophys. Res. Commun. 379, 1107-1113
31. Agarwal, V., and Bell., G. W., Nam, J. W., and Bartel, D. P. (2015) Predicting effective microRNA target sites in mammalian mRNAs. Elife 10.7554/eLife.05005
32. Lembo, A., Di Cunto, F., and Provero, P. (2012) Shortening of 3'UTRs correlates with poor prognosis in breast and lung cancer. PLoS ONE 7, e31129
33. Mayr, C, and Bartel, D. P. (2009) Widespread shortening of 3'UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell 138, 673-684
34. An, Y., Zhang, Z., Shang, Y., Jiang, X., Dong, J., Yu, P., Nie, Y., and Zhao, Q. (2015) miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2. Cell Death Dis. 6, e1766
35. Gao, P., Tchernyshyov, I., Chang, T. C, Lee, Y. S., Kita, K., Ochi, T., Zeller, K. I., De Marzo, A. M., Van Eyk, J. E., Mendell, J. T., and Dang, C. V. (2009) c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458, 762-765
36. Guo, J., Xia, B., Meng, F., and Lou, G. (2013) miR-137 suppresses cell growth in ovarian cancer by targeting AEG-1. Biochem. Biophys. Res. Commun. 441, 357-363
37. Li, P., Ma, L., Zhang, Y., Ji, F., and Jin, F. (2014) MicroRNA-137 down-regulates KIT and inhibits small cell lung cancer cell proliferation. Biomed. Pharmacother. 68, 7-12
38. Li, X., Liu, X., Xu, W., Zhou, P., Gao, P., Jiang, S., Lobie, P. E., and Zhu, T. (2013) c-MYC-regulated miR-23a/24-2/27a cluster promotes mammary carcinoma cell invasion and hepatic metastasis by targeting Sprouty2. J. Biol. Chem. 288, 18121-18133
39. Smith, A. R., and Marquez., R. T., Tsao, W. C, Pathak, S., Roy, A., Ping, J., Wilkerson, B., Lan, L., Meng, W., Neufeld, K. L., and Sun., X. F., and Xu, L. (2015) Tumor suppressive microRNA-137 negatively regulates Musashi-1 and colorectal cancer progression. Oncotarget 6, 12558-12573
40. Zaman, M. S., Thamminana, S., Shahryari, V., Chiyomaru, T., Deng, G., Saini, S., Majid, S., Fukuhara, S., Chang, I., Arora, S., Hirata, H., Ueno, K., Singh, K., Tanaka, Y., and Dahiya, R. (2012) Inhibition of PTEN gene expression by oncogenic miR-23b-3p in renal cancer. PLoS ONE 7, e50203
41. Zhu, X., Li, Y., Shen, H., Li, H., Long, L., Hui, L., and Xu, W. (2013) miR-137 inhibits the proliferation of lung cancer cells by targeting Cdc42 and Cdk6. FEBS Lett. 587, 73-81
42. Di Leva, G., Garofalo, M., and Croce, C. M. (2014) MicroRNAs in cancer. Annu. Rev. Pathol. 9, 287-314
43. Kasinski, A. L., and Slack, F. J. (2011) Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat. Rev. Cancer 11, 849-864